SCHEMBL6033150

SCHEMBL6033150

Cc1ccc(C(N)CS(=O)(=O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 1/20 0.42
GABBR1 Q9UBS5 1/20 0.42
GRIA4 P48058 1/20 0.39
GBA1 P04062 1/20 0.39
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
ACHE P22303 2/20 0.38
BCHE P06276 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
ALOX5 P09917 1/20 0.37
KIF11 P52732 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29072442 0.81 S1PR2 (0.40) GRIA4GBA1CA1CA2ACHE
SCHEMBL6034394 0.81 GABBR2 (0.42) GABBR2GABBR1GBA1F2PRSS1
SCHEMBL6033113 0.81 GABBR2 (0.42) GABBR2GABBR1CA1CA2CA9
SCHEMBL6032624 0.81 GABBR2 (0.64) GABBR2GABBR1CA1CA2CYP2D6
SCHEMBL27721990 0.80 GBA1 (0.49) GBA1ALDH1A1F2
SCHEMBL2486785 0.80 GBA1 (0.49) GBA1ALDH1A1F2
SCHEMBL27662674 0.79 GABBR2 (0.45) GABBR2GABBR1CA1CA2CA9
SCHEMBL29072409 0.79 S1PR2 (0.38) GBA1CA1CA2ACHEBCHE
SCHEMBL6034129 0.76 HTT (0.48) ALDH1A1ALOX5CYP2D6
SCHEMBL28956493 0.75 ALDH1A1 (0.49) GBA1CA1CA2ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1635909-A2 TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES Neurochem (International) Limited (CH) 2006-03-22 EP disclosed
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2005-02-17 US disclosed
WO-2005000406-A2 TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases APP, PSEN1, PSEN2 GABBR2 203/4885GABBR1 144/4885GRIA4 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.